GlassScriptPhysician profile
Travis Lee Lockwood
NPI 1295383172
$2,856.67
in general payments reported to CMS, 2019-2025
24 companies · $612 in 2025
The $612 reported for 2025 was more than what 75% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $273 · 2023: $542 · 2024: $1,430 · 2025: $612.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,584.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,584.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,072.59 | 2022-2025 | Catalyft Pl Expandable Interbody System, Stealthstation S8 Platform, Percept PC Brainsense |
| Abbvie INC. | $172.13 | 2022-2024 | |
| Intrinsic Therapeutics | $167.15 | 2024 | Barricaid Acd (Annular Closure Device) |
| Depuy Synthes Sales INC. | $136.99 | 2025 | Synthecel, Trumatch |
| Imperative Care, INC | $135.93 | 2022-2025 | Zoom 88-T Large Distal Platform |
| Boston Scientific Corporation | $125.00 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $119.50 | 2023-2024 | Hyqvia |
| Teva Pharmaceuticals USA, INC. | $113.10 | 2023-2024 | Austedo Xr |
| Livanova USA, INC. | $97.58 | 2023-2024 | Vns Therapy Sentiva Model 1000 Generator |
| Ucb, INC. | $94.49 | 2024 | Fintepla, Briviact |
| Neurelis, INC. | $93.71 | 2024 | Valtoco |
| Neurocrine Biosciences, INC. | $92.81 | 2024 | Ingrezza |
| Si-Bone, INC. | $77.52 | 2025 | |
| Acadia Pharmaceuticals INC | $64.96 | 2024 | Daybue |
| Lilly USA, LLC | $60.20 | 2024 | Amyvid, Kisunla |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Csl Behring | $44.48 | 2024 | Hizentra |
| Octapharma USA, INC. | $40.00 | 2023-2024 | Panzyga |
| Averitas Pharma INC. | $30.02 | 2023 | Qutenza |
| Catalyst Pharmaceuticals, INC. | $26.49 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $22.07 | 2024 | |
| Ge Healthcare | $21.33 | 2024 | |
| Vanda Pharmaceuticals INC. | $19.60 | 2024 | Ponvory |
| Genentech USA, INC. | $15.81 | 2024 | Enspryng, Ocrevus |
| Lundbeck LLC | $13.21 | 2024 | Vyepti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Travis Lockwood listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.